CDA Expression Measurement for Antitumor Compound Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges due to resistance mechanisms in cancer cells, necessitating the identification of new markers to predict the effectiveness of antitumor compounds and select appropriate treatments, particularly for cancers with varying Cytidine Deaminase (CDA) expression levels.
Innovation Solution
Measuring CDA expression levels in cancer samples to predict the efficacy of specific antitumor compounds like aminoflavone or dasatinib based on CDA expression status, allowing for personalized treatment selection by comparing CDA levels to reference expressions, and using kits with detection means such as primers, probes, and antibodies to facilitate this process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat cancer, then cancer cells may be killed, but cancer cells develop resistance through intrinsic or acquired mechanisms
Solution Approach 1:
The patent applies preliminary action by measuring CDA expression levels in cancer samples before initiating treatment. This pre-treatment assessment allows clinicians to predict which antitumor compound will be most effective and select the appropriate therapy in advance, avoiding the development of resistance by choosing the right initial treatment strategy based on the cancer's molecular profile
2Reliability
If treatment is selected without knowing CDA expression level, then treatment can be administered, but the effectiveness cannot be predicted and patient selection is suboptimal
Solution Approach 1:
The patent implements preliminary action by conducting CDA expression level measurement before treatment selection. This advance characterization of the cancer's molecular profile provides crucial information that guides subsequent treatment decisions, enabling predictable selection of effective antitumor compounds based on the cancer's CDA status
Solution Approach 2:
The patent applies feedback by using CDA expression level information to guide treatment selection and monitor treatment response. The measured CDA levels provide feedback about the cancer's molecular characteristics, allowing clinicians to select treatments that are most likely to succeed and adjust therapy based on the cancer's response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables targeted treatment strategies by identifying CDA-deficient or proficient tumors, enhancing the effectiveness of aminoflavone and dasatinib treatments respectively, and potentially opening new avenues for cancer therapy by defining subgroups of cancers with distinct sensitivities.
Implementation Method 1
Cytidine deaminase (CDA) is an enzyme of the pyrimidine salvage pathway catalyzing the hydrolytic deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.